These results importantly highlight an unmet medical need, that is the urgency to identify alternative therapeutic strategies for AML patients with elevated IL1RAP expression, as these patients do not appear to benefit from standard chemotherapy or HSCT. This evidence concerns the gene IL1RAP and acute myeloid leukemia.